Hims & Hers Lifts Sales Outlook as GLP‑1 Pivot Squeezes Profits

Overview

• Hims & Hers raised its full‑year revenue target to $2.8 billion to $3.0 billion and cut its adjusted EBITDA goal to $275 million to $350 million.
• The company said its move to branded GLP‑1 weight‑loss drugs such as Wegovy is adding subscribers and revenue but pressuring margins.
• In Q1, revenue reached $608.1 million, U.S. sales fell 8% to $529.9 million, international sales rose to $78.2 million, subscribers topped 2.58 million, and adjusted EBITDA fell to $44.3 million.
• For Q2, the company guided to $680 million to $700 million in revenue and $35 million to $55 million in adjusted EBITDA.
• After the report, the stock swung lower as Bank of America cut its price target to $30 and kept a Neutral rating, calling for a reset to near‑term expectations.